Therapeutic arteriogenesis by factor-decorated fibrin matrices promotes wound healing in diabetic mice.
Rosalinda D'AmicoCamilla MalucelliAndrea UccelliAndrea GrossoNunzia Di MaggioPriscilla S BriquezJeffrey A HubbellThomas WolffLorenz GürkeEdin MujagicRoberto Gianni-BarreraAndrea BanfiPublished in: Journal of tissue engineering (2022)
Chronic wounds in type-2 diabetic patients present areas of severe local skin ischemia despite mostly normal blood flow in deeper large arteries. Therefore, restoration of blood perfusion requires the opening of arterial connections from the deep vessels to the superficial skin layer, that is, arteriogenesis. Arteriogenesis is regulated differently from microvascular angiogenesis and is optimally stimulated by high doses of Vascular Endothelial Growth Factor-A (VEGF) together with Platelet-Derived Growth Factor-BB (PDGF-BB). Here we found that fibrin hydrogels decorated with engineered versions of VEGF and PDGF-BB proteins, to ensure protection from degradation and controlled delivery, efficiently accelerated wound closure in diabetic and obese db/db mice, promoting robust microvascular growth and a marked increase in feeding arterioles. Notably, targeting the arteriogenic factors to the intact arterio-venous networks in the dermis around the wound was more effective than the routine treatment of the inflamed wound bed. This approach is readily translatable to a clinical setting.
Keyphrases
- wound healing
- growth factor
- vascular endothelial growth factor
- blood flow
- endothelial cells
- reduced graphene oxide
- smooth muscle
- vascular smooth muscle cells
- quantum dots
- adipose tissue
- type diabetes
- metabolic syndrome
- highly efficient
- weight loss
- early onset
- clinical practice
- platelet rich plasma
- cancer therapy
- magnetic resonance
- computed tomography
- surgical site infection
- drug delivery
- gold nanoparticles
- insulin resistance
- angiotensin ii
- replacement therapy
- bone regeneration
- recombinant human